Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features

Daniela Sia, Yang Jiao, Iris Martinez-Quetglas, +16

Gastroenterology

HepatologyImmune-specific ClassImmunologyHistopathologyHepatitis +8

β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma

Marina Ruiz de Galarreta, Erin Bresnahan, Pedro Molina-Sánchez, +20

Cancer Discovery

Integrative Molecular Analysis of Intrahepatic Cholangiocarcinoma Reveals 2 Classes That Have Different Outcomes

Daniela Sia, Yujin Hoshida, Augusto Villanueva, +20

Gastroenterology

Tumor BiologyDifferent OutcomesHepatologyBiliary TractMedicine +12

Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis

Sebastián Morán, Anna Martínez‐Cardús, Sergi Sayols, +29

The Lancet Oncology

OncologyTumor HeterogeneityUnknown PrimaryMedicineEpigenetic Change +11

Combining Clinical, Pathology, and Gene Expression Data to Predict Recurrence of Hepatocellular Carcinoma

Augusto Villanueva, Yujin Hoshida, Carlo Battiston, +16

Gastroenterology

OncologyHepatologyMedicinePathologyCancer Genomics +9

Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer

Supriya K. Saha, Christine A. Parachoniak, Krishna S. Ghanta, +23

Nature

Tumor BiologyPromote Biliary CancerHepatologyBiliary CancerLiver Physiology +9

Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations

Silvia Affò, Ajay Nair, Francesco Brundu, +34

Cancer Cell

Biliary CancerHepatobiliary TumorPathologyFibroblast Growth FactorBiliary Cancers +4

Intratumoral heterogeneity and clonal evolution in liver cancer

Bojan Losic, Amanda J. Craig, Carlos Villacorta-Martín, +25

Nature Communications

Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial

Roser Pinyol, Robert Montal, Laia Bassaganyas, +27

Gut

Massive parallel sequencing uncovers actionable FGFR2–PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma

Daniela Sia, Bojan Losic, Agrin Moeini, +20

Nature Communications